Abstract
Background Patients admitted to the intensive care unit often have low serum levels of magnesium, phosphate, and zinc. We aim to describe the prevalence, management, characteristics, and outcomes of patients with low levels of these minerals in a large cohort of Danish ICU patients.
Methods In this multicenter cohort, we will include all adult ICU patients admitted to one of 10 ICUs during a six years period. Patients will be excluded if the ICU admission is post-operative after planned surgery, length of stay is <24 hours, they are transferred from ICUs not participating in the study, or are without measurements of neither magnesium, phosphate nor zinc. First, we will do a descriptive assessment of the prevalence of low serum levels and management of supplementation according to different patient characteristics. Second, we will conduct a cohort study using prospectively registered outcome data, to assess associations between serum levels of magnesium, phosphate, and zinc respectively, and each of two principal outcomes: time to successful extubation and incident tachyarrhythmia. We will use a joint modelling approach for estimating the strengths of associations, combining time to event data and longitudinal data from repeated measurements of serum levels.
Discussion This study will provide information from a very large cohort of Danish ICU patients. Strengths of the study will be the large number of patients, the interconnection of data from several registers, and for the association analysis the use of a statistical approach making the optimal use of the repeated measures of serum levels. Limitations will be the risk of bias from unmeasured or unregistered confounding factors, and the lack of randomization in the observational design, which will prevent us from interpreting possible associations between serum levels and outcomes as definite effects on the outcome.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: for the submitted manuscript we had financial support from: The Research foundation of Rigshospitalet, Copenhagen University Hospital, Denmark; Novo Nordisk Foundation (Grant agreement NNF14CC0001);The Innovation Fund Denmark (Grant agreement 5153-00002B). AP has received funding for other work from: Sygeforsikringen danmark; AM-Pharma and Pfizer during the past 36 months
Funding Statement
For the submitted manuscript we had financial support from: The Research foundation of Rigshospitalet, Copenhagen University Hospital, Denmark; Novo Nordisk Foundation (Grant agreement NNF14CC0001);The Innovation Fund Denmark (Grant agreement 5153-00002B).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study has been approved by the Danish Data Protection Agency and the Danish Patient Safety Authority. All data will be handled with confidentiality and participants will be anonymized.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data we will assess for this study cannot readily be shared because of national and EU regulations. However, data is available for use in secure, dedicated environments via application to the Danish Patient Safety Authority and the Danish Health Data Authority. Analytical code used in the study will be made publicly available.
